M&A / Deals Incyte gobbles up Star’s Vega haematology unit in $2bn deal PharmaphorumIncyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Incyte has agreed to buy Star Therapeutics’ Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD. Hematology Read full story Post navigation Previous: Roche doubles down on BTK with $2.3bn Nurix dealNext: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
